Skip to content

Study · Other design · 2018

10 results

Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.

Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, Madsen KG, Schéele SG, Alanentalo T, Kirk RK, Pedersen BL, Skyggebjerg RB and 10 more

Show all authors

Benie AJ, Strauss HM, Wahlund PO, Bjerregaard S, Farkas E, Fekete C, Søndergaard FL, Borregaard J, Hartoft-Nielsen ML, Knudsen LB

Science translational medicine1 Nov 2018Cited by 382 (Europe PMC)

PMID30429357 (opens in a new tab)DOI10.1126/scitranslmed.aar7047 (opens in a new tab)PepBankPUB-30429357
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

7 results from studies that gave the peptide. 3 results from people.

  1. 01HumanOther designPharmacokinetics

    In clinical studies, absorption of oral semaglutide coformulated with SNAC took place in the stomach.

    In plain wordsIn people, oral semaglutide with SNAC was absorbed in the stomach.

    Peptide
    Semaglutide
    Outcome
    Not applicableSite of oral semaglutide absorption
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    clinical and preclinical dog studies revealed that absorption of semaglutide takes place in the stomach, is confined to an area in close proximity to the tablet surface, and requires coformulation with SNAC.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
  2. 02HumanOther designPharmacokinetics

    In clinical studies, oral semaglutide absorption was confined to an area in close proximity to the tablet surface.

    In plain wordsIn people, oral semaglutide was absorbed only in the stomach area close to the tablet.

    Peptide
    Semaglutide
    Outcome
    Not applicableLocalisation of absorption near the tablet
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    is confined to an area in close proximity to the tablet surface, and requires coformulation with SNAC.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
  3. 03HumanOther designPharmacokinetics

    In clinical studies, absorption of oral semaglutide required coformulation with SNAC.

    In plain wordsIn people, oral semaglutide needed SNAC in the tablet to be absorbed.

    Peptide
    Semaglutide
    Outcome
    Not applicableRequirement for SNAC coformulation
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    requires coformulation with SNAC.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In dog studies, absorption of oral semaglutide coformulated with SNAC took place in the stomach.

    In plain wordsIn dogs, oral semaglutide with SNAC was absorbed in the stomach.

    Peptide
    Semaglutide
    Outcome
    Not applicableSite of oral semaglutide absorption
    Study

    dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (dog).

    Source sentences

    Summary
    clinical and preclinical dog studies revealed that absorption of semaglutide takes place in the stomach, is confined to an area in close proximity to the tablet surface, and requires coformulation with SNAC.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    In dog studies, oral semaglutide absorption was confined to an area in close proximity to the tablet surface.

    In plain wordsIn dogs, oral semaglutide was absorbed only in the stomach area close to the tablet.

    Peptide
    Semaglutide
    Outcome
    Not applicableLocalisation of absorption near the tablet
    Study

    dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (dog).

    Source sentences

    Summary
    is confined to an area in close proximity to the tablet surface, and requires coformulation with SNAC.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
  6. 06AnimalAnimal study (in vivo)Pharmacokinetics

    In dog studies, absorption of oral semaglutide required coformulation with SNAC.

    In plain wordsIn dogs, oral semaglutide needed SNAC in the tablet to be absorbed.

    Peptide
    Semaglutide
    Outcome
    Not applicableRequirement for SNAC coformulation
    Study

    dogn: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study (dog).

    Source sentences

    Summary
    requires coformulation with SNAC.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.
  7. 07LabOther designMechanism

    The absorption mechanism of semaglutide was compound specific and transcellular.

    In plain wordsIn lab tests, semaglutide was absorbed through cells by a route specific to this compound.

    Peptide
    Semaglutide
    Outcome
    Not applicableSemaglutide absorption pathway
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated · oralAs given in this study.

    Source sentences

    Summary
    The mechanism of absorption is shown to be compound specific, transcellular, and without any evidence of effect on tight junctions.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 08LabNot a test of Semaglutide aloneOther designMechanism

    SNAC protected against enzymatic degradation through local buffering.

    In plain wordsIn lab tests, SNAC protected the peptide from being broken down by enzymes through local buffering.

    Peptide
    Semaglutide
    Outcome
    Not applicableSNAC protection against enzymatic degradation
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    SNAC protects against enzymatic degradation via local buffering actions and only transiently enhances absorption.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 09LabNot a test of Semaglutide aloneOther designMechanism

    SNAC only transiently enhanced absorption.

    In plain wordsIn lab tests, SNAC raised absorption only for a short time.

    Peptide
    Semaglutide
    Outcome
    Not applicableSNAC enhancement of absorption
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    only transiently enhances absorption.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 10LabNot a test of Semaglutide aloneOther designMechanism

    There was no evidence that the SNAC tablet formulation affected tight junctions.

    In plain wordsIn lab tests, there was no sign that the tablet formulation affected tight junctions between cells.

    Peptide
    Semaglutide
    Outcome
    No significant changeEffect on tight junctions
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    without any evidence of effect on tight junctions.
    1 context sentence
    Summary · context
    Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.